# Cost-effectiveness of Cerebrolysin as an add-on treatment for neurorecovery after traumatic brain injury

**Authors:** Stefan Strilciuc, Diana Alecsandra Grad, Cristian Vlădescu, Anca Dana Buzoianu, Carmen Albu, Dafin Fior Mureșanu

PMC · DOI: 10.25122/jml-2025-0087 · Journal of Medicine and Life · 2025-04-01

## TL;DR

This study shows that Cerebrolysin, when added to standard care, is likely cost-effective for improving recovery in patients with moderate traumatic brain injury.

## Contribution

The study provides new evidence on the cost-effectiveness of Cerebrolysin for moderate TBI using real clinical trial data.

## Key findings

- Cerebrolysin showed a high probability of being cost-effective in over 80% of moderate TBI patients based on GOSE scores.
- Improvements in anxiety and depression scores were observed in over 95% of patients treated with Cerebrolysin.
- A model-based approach is recommended to address biases beyond the 90-day trial observation period.

## Abstract

Traumatic brain injuries (TBIs) are a leading cause of death and long-term disability worldwide, with incidence and injury mechanisms varying by age group and region. Impairment of functional status, diagnoses of anxiety and depression are encountered post-TBI. Studies have shown that Cerebrolysin can have positive effects among TBI survivors. We conducted a cost-effectiveness analysis (CEA) among patients with moderate TBI, using data from the CAPTAIN II trial. This exercise was carried out on a three-month timeline from the provider’s perspective. Two models were incorporated in the CEA: control (placebo group) and treatment (Cerebrolysin group). Our analysis showed that Cerebrolysin had a high probability of being cost-effective, based on Glasgow Outcome Scale Extended (GOSE) (in over 80% of patients with moderate TBI), Hospital Anxiety and Depression Scale (HADS) Depression and Anxiety scores (for the former two, in over 95% of patients with moderate TBI), when assuming a lasting effect (12 months) of the CAPTAIN trial intervention protocol. A model-based approach is needed to account for potential sources of bias beyond the 90-day observation period of this clinical trial. Furthermore, economic evaluations incorporating patients diagnosed with all TBI severities are needed.

## Linked entities

- **Diseases:** traumatic brain injury (MONDO:0858950), anxiety (MONDO:0005618), depression (MONDO:0002050)

## Full-text entities

- **Diseases:** TBI (MESH:D000070642), Impairment of functional status (MESH:D013226), Anxiety (MESH:D001007), Depression (MESH:D003866), death (MESH:D003643)
- **Chemicals:** Cerebrolysin (MESH:C006952)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12094318/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12094318/full.md

## References

60 references — full list in the complete paper: https://tomesphere.com/paper/PMC12094318/full.md

---
Source: https://tomesphere.com/paper/PMC12094318